An inspection regarding API manufacturing standards was conducted at a facility in Srikakulam district, involving Aurobindo Pharma and Auroactive Pharma.

1 report, 1 independent Updated Jun 27

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

United States Food and Drug Administration

Keep exploring

Part of

The US Food and Drug Administration conducted a PAI inspection at a subsidiary of Aurobindo Pharma, a company with operations in India and offices in Kerala. All 1 developments

The entities involved

United States Food and Drug Administration
agency of the US Department of Health and Human Services
- FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09
- FDA inspection at Unichem Laboratories Limited's Goa facility found procedural enhancements needed, leading to market reaction.Sun 10:21

Related events

A routine inspection of a GMP manufacturing unit in Visakhapatnam, Andhra Pradesh, was conducted by the United States Food and Drug Administration and confirmed regulatory compliance.Sep 2

Coverage

Newest first; wire copies grouped

Jun 27equitybulls.com